redhot diagnostics is based on the idea that if a company has set up all the processes for taking a prototype to market, so can these processes be used over and over again. All R&D companies that want to evolve to a production and marketing company has to invent the wheel over and over again.


We can help researchers with good diagnostic product ideas to get to market much faster by using our company set up.

We have a distribution network with great knowledge hot to market and sell the product. It is always difficult to be a one-product-company in negotiation with distributors, avoid that with a joint venture with redhot.


Håkan RandahlHåkan Randahl, Chief Executive OfficerPhD 1984 at Karolinska Institutet in biochemistry. Research between 1985 – 87 post doc at UC Berkeley, in California, thereafter at Department of Tumor Biology, Karolinska Institutet. Experience from small biotech companies within the diagnostic sector. CEO at PhPlate AB and Bactus AB, 1999 – 2004 respectively 2005 to 2009.
Phone: +46 (0)704 93 36 64
Johan RydénJohan Rydén, Vice President Business DevelopmentM.Sc.1992 at Chalmers University of Technology. Since then worked in the field of Medical Technology; in the large corporate setting with clinical trials of new indications at Medtronic Inc and Pacesetter Inc; in the small academic start-up setting as CEO for Noster AB and Alimenta Medical AB who both developed in-vivo and in-vitro diagnostic products, and in TransCutan AB who develops intracorporeal access products.
Phone: +46 (0) 709 95 59 14
Anette BergmanAnette Bergman, Chief Production OfficerBiomedical Scientist (BS) in microbiology 1983. Worked as BS at a hospital virology and bacteriology laboratory between 1984-1987, and with production of veterinary vaccine between 1987-1990. Has held various positions at the diagnostic companies Boule and Bactus between 1990-2011. From BS, via quality manager, to the head of manufacturing.
Phone: +46 (0) 706 81 99 91


Thomas BuschThomas Busch, M.Sc. Cell & Molecular biologyCEO and part owner Nordic Biolabs AB since 2000. Prior, (1994 – 1999), he was site Manager Sweden Life Technologies Inc and, 1988 – 1994, Sales and Product management at Labdesign AB. Between 1986 – 1988 Thomas worked as a laborant (dep of immunotoxicology) at Astra Safety Assessment.
Phone: +46 (0)706 03 78 12
Håkan RandahlHåkan Randahl, founder of redhot diagnostics
Phone: +46 (0)704 93 36 64
Johan RydénJohan Rydén, founder of redhot diagnostics (chairman of the board)
Phone: +46 (0) 709 95 59 14
Mattias ErikssonMattias Eriksson, B.Sc.Molecular BiologyInvestment manager at Innovationsbron AB. Has long prior experience in the pharmaceutical industry; from Sales Representative at Pfizer AB (1992-1995) to Vice President Product Development at Innate AB (2006-2009) via various positions in-between at AstraZeneca, Uman Genomics, and Astra Arcus.
Phone: +46 (0)70 539 39 98

Our historypilner

The founders have separately, during long time, seen the frustrations among small research oriented companies or academic set-ups in the diagnostic field struggling to set up their business processes and market their products. Each company is forced to invent the wheel over and over again.A couple of years ago the founders realized they shared a common idea and vision about how to solve the above problem. During a six-month time the ideas was formulated into a business concept that has the potential to revolutionize the diagnostic field.

The opportunity to start-up RedHot came in the meeting between the founders and Umeå Biotech Incubator (UBI). UBI was willing to give a smaller investment that made it possible for the founders to investigate the business concept’s validity.During this time the founders came in contact with prof Per Venge at Akademiska Hospital in Uppsala, who has developed several diagnostic analyses in his R&D company Diagnostics Development AB. Currently none of his products are CE-marked. The founders and Per Venge agreed on collaboration of three of his analyses that from the founder’s point of view will be used to build up the business around.Since the company was started, several other researchers have shown interest in using the reshot concept for their product ideas. Two of which we have deepened our discussions around jointly owned R&D companies.

Joint Venture Evaluationpilner

The evaluation of the projects follows a standard checklist that we go through in collaboration with the scientist. The major issues are:

  • How near a prototype is the idea. redhot does not invest in research.
  • How well is the product validated
  • Possibility for scaling up production from prototype to industrial scale
  • What classification will the device have for CE labeling, are there any particular claims
  • IPR, is there a patent or any other intangibles that makes the product difficult to copy
  • Unique selling point
  • Who is the end-customer
  • Market
  • Is there any key opinion leader that could be interested in the product

Download the checklist here.


Redhot is ISO 13485 certifiedintertek Our aim is to produce better diagnostics for a reliable treatment of patients. We do this in cooperation with our affiliated companiesThe policy is to clarify redhot´s approach to quality and to make the quality policy known to all employees as well as to our affiliated companies and customers. In addition, it aims to maintain and ensure redhot’s competitiveness and profitability.


All R&D work has to be made in the R&D companies and be externally financed.Redhot will take responsibility for making the prototype into a product that could be sold to a customer. That includes all quality aspects that has to be considered including a CE-labeling of the product, clinical validation, up-scaling of the production method, packing into kit, and presentation of the product for distributors.


Redhot diagnostic has a production facility in Umeå.
We have the competence for the production of most types of diagnostics independent of the technical platform.
For contract production, please take contact with us.